MEG-01 Xenograft Model Service for CML

The MEG-01 cell line provides a specialized and highly representative in vivo platform for investigating Chronic myeloid leukemia (CML), particularly regarding its unique megakaryoblastic features and Philadelphia chromosome status. As a premier pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision MEG-01 Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your CML drug discovery and development pipeline.

Overview of MEG-01 Xenograft Model for CML

The MEG-01 xenograft model is an established in vivo translational system widely utilized in hematological oncology research for the study of CML. Originally derived from a patient in the blast crisis phase of the disease, MEG-01 cells exhibit distinct megakaryoblastic differentiation potential alongside the hallmark BCR-ABL1 fusion. By transplanting these human cells into highly permissive, immunodeficient rodent hosts, this model effectively reproduces the systemic dissemination, bone marrow homing kinetics, and peripheral blood pathophysiological profiles characteristic of progressive human CML.

Biologically, the MEG-01 model is highly valued for its consistent engraftment profiles and predictable disease progression, which provide investigators with a reliable experimental window for evaluating complex dosing schedules and pharmacodynamics. This model preserves critical human myeloid molecular features, including lineage-specific marker expression and intracellular signaling pathways that drive blast expansion. Consequently, the MEG-01 model is extensively deployed in pre-clinical screening programs to assess the anti-leukemic potency of novel small-molecule inhibitors, targeted monoclonal antibodies, and combination therapeutic regimens in a physiologically relevant in vivo setting.

Cell Line Information: MEG-01

The MEG-01 cell line is derived from the bone marrow of a patient diagnosed with CML in the blast crisis phase. These cells grow as suspension cultures under standard in vitro laboratory parameters, maintaining a stable megakaryoblastic phenotype that serves as a robust proxy for hematological cancer research.

Our Services

Workflow of MEG-01 Xenograft Model Construction

• Cell Culture & Quality Control: Human MEG-01 cells are expanded in vitro using certified nutrient suspension media under optimized growth parameters. STR authentication and mycoplasma clearance verification are completed prior to inoculation to ensure absolute phenotypic identity and biological purity.
• Host Selection & Acclimatization: Standardized, healthy immunodeficient mice are sourced from validated vendors. The animals undergo a dedicated acclimatization phase to stabilize baseline biological and physiological metrics.
• Precision Inoculation: A calibrated suspension of high-viability MEG-01 cells is prepared in a sterile physiological buffer. The cellular suspension is precisely inoculated in vivo into the host cohorts via tail vein intravenous routes to facilitate systemic leukemic distribution.
• Longitudinal Growth Tracking: Following inoculation, disease progression is systematically monitored using FACS to detect human CD45+ cells or specific myeloid markers in peripheral blood. Animal weight, physical clinical indicators, and systemic disease burden are documented routinely.
• Stratification & Dosing: Once peripheral leukemic chimerism reaches a predetermined, statistically optimal range, the mice are randomized into matched experimental cohorts to ensure balanced baseline systemic dimensions before the initiation of customized therapeutic dosing regimens.

Fig 1. MEG-01 Xenograft Model Construction Workflow

Case Study - MEG-01 Xenograft Model Development

A pre-clinical validation study was conducted using the MEG-01 xenograft model to evaluate the therapeutic efficacy of a novel targeted inhibitor designed for CML. Following precision intravenous inoculation of human MEG-01 cells into immunodeficient mice, the animals exhibited steady, systemic leukemic engraftment and highly predictable disease progression across all study cohorts. Animals assigned to the active treatment group demonstrated a clear, statistically significant reduction in circulating leukemic blasts and prolonged survival times compared to the vehicle control, confirming the model's high sensitivity and predictive reliability for screening targeted CML therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing diverse hematological and myeloid lineages, providing highly reproducible in vivo translational platforms for complex leukemia research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready data report providing comprehensive digital caliper metrics and robust statistical validations.

Contact us

Accelerating your CML pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our MEG-01 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.